Pharma VC Funds

Courtyard Ventures is an early-stage venture capital firm based in Berkeley, California, focused on investing in startups that emerge from the UC Berkeley ecosystem. Founded in 2021, the firm supports student and alumni-led ventures, leveraging its connection to UC Berkeley’s innovative network. Courtyard Ventures specializes in sectors like business software, education technology, and logistics, aiming to fuel startups with high growth potential. The fund has backed companies like Ruuf, a platform in the information services space, and EdVisorly, an education-focused startup. Courtyard typically invests at the seed stage, providing early funding and strategic support to help startups navigate the complexities of scaling their businesses. Led by partners such as Dogakan Toka and Kevin Chang, Courtyard Ventures focuses on nurturing founders through its extensive network, especially within the Haas MBA program and other Berkeley alumni connections. With an eye on building category-leading companies, Courtyard Ventures is well-positioned to drive innovation from the university's entrepreneurial ecosystem.

Covalent Ventures is a globally connected food and health impact investor founded in 2021 and headquartered in Auckland, New Zealand, with additional presence in Switzerland. The firm focuses on Series A health and wellness investments, actively working with portfolio companies to scale into major global markets across the Asia-Pacific region, Switzerland, and the United States. Partner Kelvin Keh brings more than 20 years of international healthcare experience spanning biotech and pharma, medical devices, digital health, nutrition, and consumer packaged goods. The combined investment team holds 50 or more years of sector experience and a track record of at least 17x growth. Covalent deploys checks of $500,000 to $4 million per company with a sweet spot of $2 million, investing across seed through Series B stages in 11 portfolio companies. Sector coverage spans food systems, nutrition science, biotech, pharmaceutical, medical devices, digital health, healthcare systems, novel ingredients, and cell and gene therapy — a deliberately broad mandate within the health and food impact thesis. The firm's investment philosophy holds that human health is inseparable from food systems, and that the most consequential companies in this space bridge both domains. Covalent works alongside founders to access green and brownfield markets — new categories as well as established markets ripe for disruption — bringing sector expertise and a global network to bear on the commercial challenges that health and food technology companies face as they scale from early traction to institutional scale.

Co-Win Ventures, founded in 2009 and based in Beijing, China, is a prominent early-stage investment firm focusing on the Technology, Media, and Telecommunications (TMT) and healthcare sectors. Their portfolio features a variety of innovative companies, including KBP Biosciences, Celsius Therapeutics, Thrive Earlier Detection, and Fluent BioSciences. The firm supports both early-stage and growth-stage companies, providing capital and strategic guidance to help them scale successfully. Co-Win Ventures has a strong presence in both China and the USA, leveraging its extensive network to foster innovation and growth. Their investment approach combines financial backing with hands-on support, ensuring that their portfolio companies have the resources they need to thrive in competitive markets. By focusing on sectors with high growth potential, Co-Win Ventures aims to drive advancements in technology and healthcare, contributing to significant industry developments. Their commitment to supporting visionary entrepreneurs has made them a key player in the venture capital landscape.

CPT Capital, based in London, is the venture capital arm of a leading private family office. The firm specializes in investing in companies revolutionizing the food and materials technology sectors, particularly in the realm of alternative proteins. CPT Capital's mission is to drive this revolution by partnering with visionary founders and supporting them from pre-seed stages through to IPO or sale. As a long-standing investor in the alternative protein space, CPT Capital focuses on plant-based proteins, biomass fermentation, recombinant proteins, and cultivated meat. Their portfolio includes groundbreaking companies like Impossible Foods, Beyond Meat, and Upside Foods, all of which are at the forefront of developing sustainable and innovative food solutions. CPT Capital seeks companies with products that directly replace animal-derived products and possess a strong technological or intellectual property component. The firm is geographically diverse, with investments spanning the US, Israel, Europe, the UK, and Asia. The firm is dedicated to addressing global challenges related to food production and sustainability, aiming to replace traditional animal protein sources with more sustainable alternatives. This approach not only promises environmental benefits but also aims to improve public health and resource efficiency.

Craft Ventures is a venture capital firm that focuses on early-stage investments in B2B software, marketplaces, and transaction-based business models. Established in 2017, Craft Ventures is led by a team of seasoned entrepreneurs and investors, including Jeff Fluhr, co-founder of StubHub, and David Sacks, former COO of PayPal. Craft Ventures' strategy includes providing more than just capital. They offer strategic support to portfolio companies, helping them build robust go-to-market strategies, optimize operations, and scale effectively. Their team comprises individuals with extensive experience in marketing, growth, and operations from successful tech startups like ClickUp and Callin. With a presence in San Francisco and a commitment to working closely with founders, Craft Ventures aims to identify and support the next generation of category-defining companies.

CRCM Ventures is a venture capital firm founded in 2004, headquartered in San Francisco, with a focus on early-stage investments in both the US and Greater China. The firm targets sectors such as healthcare and wellness, fintech, blockchain technology, media, and frontier technology. CRCM Ventures has an impressive portfolio, including three unicorns: Apollo, Blockdaemon, and Iterable. Notable public companies in their portfolio include Ginkgo Bioworks, which went public on the NYSE in 2021, and Yiju Enterprise Group, listed on the Hong Kong Stock Exchange. Additionally, CRCM has seen multiple acquisitions, such as The Drone Racing League and Spin, reflecting their success in identifying and supporting high-potential startups. The firm is led by a team of experienced professionals, including Chun Ding, who is based in San Francisco. Their investment strategy emphasizes backing innovative technology-driven companies with the potential to transform industries. CRCM Ventures combines a strong presence in Silicon Valley with deep connections in China, leveraging their dual-market expertise to drive growth and innovation in their portfolio companies. This approach allows them to provide significant value to startups looking to expand and scale their operations globally.

Creadev, established in 2002 and supported by the Mulliez family, is a global evergreen investment firm dedicated to nurturing companies that have the potential to become industry leaders. With a presence in Paris, Shanghai, New York, and Nairobi, Creadev has built a diverse portfolio across healthcare, sustainable consumption, and food sectors. One of their notable investments is Twiga Foods, a prominent food distribution platform in Kenya that uses technology to streamline the supply chain between farmers and vendors, enhancing efficiency and sustainability. Another significant investment is Victory Farms, an East African aquaculture platform addressing nutritional security through sustainable fish farming solutions. Creadev has also backed Everytable, a U.S.-based food and beverage company committed to providing affordable and healthy meals to underserved communities. In the realm of plant-based foods, Creadev has invested in The Jackfruit Company, which produces meat substitutes using jackfruit, catering to the growing demand for sustainable and healthy food options. Additionally, they support Lifen, a French health tech company offering digital solutions to improve healthcare delivery and patient management. Creadev's investment approach emphasizes long-term commitment and aligns the investment horizon with the entrepreneurial vision. They often lead funding rounds and work collaboratively with other investors to support the growth and expansion of their portfolio companies. This strategy reflects their dedication to fostering sustainable and impactful businesses globally​.

Creandum is a leading European venture capital firm that specializes in early-stage investments, focusing on technology-driven companies within the consumer, software, and hardware industries. Founded in 2003, Creandum operates from its hubs in Stockholm, Berlin, London, and San Francisco, and is renowned for its thesis-driven approach to investing. The firm's notable portfolio includes high-profile companies such as Spotify, Klarna, Bolt, Depop, and Kahoot!. Creandum has also recently raised its seventh fund, a €500 million vehicle dedicated to supporting seed and early-stage startups across Europe. This fund aims to continue backing innovative companies poised to become global leaders. Creandum's investment philosophy emphasizes long-term commitment to founders, supporting them through the various stages of their growth journey. The firm prides itself on its deep industry expertise and extensive network, which it leverages to help startups scale and succeed in competitive markets. Recent investments include companies like Prewave, a supply chain disruption solution, and Plancraft, a platform digitizing work processes in the craft industry.

Creathor Ventures is one of Germany's most established early-stage venture capital firms, founded in 2003 and headquartered in Bad Homburg with an additional office in Meilen, Switzerland. Managing over €230 million in fund volume, the firm focuses on technology-oriented companies driving industrial automation and the digitalization of healthcare. With roots in venture investing stretching back to 1984, the management team has financed more than 200 companies over three decades, making Creathor one of the longest-tenured active investors in the German-speaking tech ecosystem. Creathor leads and co-leads rounds at Seed and Series A stages, deploying checks in the €3 million to €15 million range. The firm's 96-company portfolio is concentrated in enterprise applications, life sciences, and SaaS, with AI and hardware also well represented. More than 20 portfolio companies have reached international stock exchange listings, and numerous others have completed trade sales — a track record that underlines the firm's ability to build durable technology businesses. Operating across Germany and Switzerland with a team of 15, Creathor works closely alongside portfolio companies rather than from a distance. The firm's dual expertise in enterprise technology and healthcare gives it a distinctive vantage point for identifying companies where automation and digital tools are reshaping both industry and patient outcomes.

Creative Ventures is a venture capital firm focusing on market-driven deep technology investments. They invest in early-stage B2B companies that are commercializing novel scientific and engineering innovations. Key investment sectors include climate change adaptation and mitigation, healthcare, and addressing labor shortages in industrial and service sectors. The firm prides itself on a market-first approach, ensuring that the technologies they invest in are primed to meet existing market demand rather than speculative future needs. This strategy helps mitigate risks associated with deep tech investments​ (Creative Ventures)​​ (Creative Ventures)​. Creative Ventures has been a lead or co-lead investor in 80% of their investments from the current fund, often being the first institutional investor on a company's cap table​. Notable portfolio companies include Path Robotics, Sepion Technologies, and OncoPrecision, which focus on autonomous welding robots, advanced materials for energy storage, and oncology drug efficacy, respectively​. The team, led by General Partners Alex Luce and Kulika Weizman, brings extensive expertise in areas such as material science, synthetic biology, and biotechnology.

Creator Fund is a venture capital firm focused on backing scientific founders at the pre-seed and seed stages, primarily across the UK and Europe. Founded in 2019 by Jamie Macfarlane, the fund specializes in investing in deep technology and life sciences startups that emerge from university research. With a unique model, Creator Fund operates a network of PhD students across 25+ leading European universities, helping to identify promising ventures at the earliest stages of development. Creator Fund typically invests between £100,000 to £700,000 in early-stage startups, often backing companies where at least one founder is an academic—whether a professor, PhD, or recent graduate. They have built a diverse portfolio, including companies like Baseimmune (biotechnology) and Recycleye (AI-driven waste management). Their sector focus spans deep tech areas such as artificial intelligence, robotics, quantum computing, and biotech, aiming to support founders who are pioneering breakthroughs in their fields. Their investment strategy also emphasizes long-term involvement, often supporting founders through multiple funding rounds and connecting them with a strong network of co-investors across Europe and the U.S. The fund's leadership team, alongside Macfarlane, includes seasoned professionals who bring expertise from venture capital and deep-tech industries.

Crédit Mutuel Equity, the private equity arm of Crédit Mutuel Alliance Fédérale, focuses on supporting companies at various stages of their development, from early-stage growth to transformation and international expansion. Based in France, the firm has a diverse portfolio encompassing over 350 companies globally. Key investments include UroMems, which develops implantable mechatronics technology for medical applications; Quandela, a leader in quantum photonics; and HarfangLab, a cybersecurity company specializing in endpoint detection and response. Other notable companies in their portfolio are Latitude, a space launcher operator, and MentorShow, an EdTech SaaS platform. Crédit Mutuel Equity invests across multiple sectors, including healthcare, technology, consumer goods, energy, real estate, and logistics. They typically support companies with innovative business models and substantial growth potential, providing both financial investment and strategic guidance to help them scale and succeed.

Crescendo Venture Partners (CR-VP) is a Tel Aviv-based venture capital firm focused on investing in early-stage companies that leverage next-generation technologies such as Big Data, AI, and Machine Learning. Founded by a team of seasoned venture capitalists with over 75 years of combined experience, CR-VP seeks to partner with ambitious entrepreneurs who aim to build sustainable, profitable businesses that can become category leaders in their respective industries. The firm emphasizes supporting startups that offer simple, scalable solutions to complex problems across substantially-sized markets. CR-VP's approach involves not only providing capital but also offering strategic support to help companies navigate the journey from inception to exit. CR-VP's portfolio includes notable companies like WalkMe, which went public, and Cyota, which was acquired by RSA. The firm also collaborates with the Geneva-based Crescendo Group, providing access to untapped sources of capital and broadening the reach to European, LATAM, and Asian markets.

Crista Galli Ventures is a London-based evergreen venture capital fund founded in 2019, operating as the healthtech investment arm of IPQ Capital — the family office of Dr Fiona Pathiraja and Søren Fryland Møller, who serve as the fund's two partners. Also active from Copenhagen, the firm focuses on European healthtech startups led by clinicians and domain experts, investing at the nexus of biology, technology, and medicine. The evergreen structure allows the fund to maintain long-term positions and support founders through extended development timelines typical of healthcare innovation. Crista Galli invests at Seed and Series A stages, writing checks from €100,000 to £3 million, across digital health, AI-enabled clinical tools, medical devices, and personalized medicine. With 48 investments across the UK, Germany, France, Spain, and the Netherlands, the portfolio includes Bugbiome, Kanjo Health, CardiaTec, Inne, Keleya, Leda Health, and aeon — spanning fertility, cardiology, digital therapeutics, and wearable health monitoring. The firm's clinical and scientific credibility is central to its value proposition. Dr Pathiraja's background as a physician-investor enables Crista Galli to evaluate clinical validity and adoption potential in ways that purely financial investors cannot. The fund backs companies with strong user adoption potential and genuine capacity to solve real-world healthcare problems at scale.

Crosslink Capital, founded in 1989, is an early-stage venture capital firm based in Menlo Park and San Francisco. The firm focuses on investing in disruptive and market-transforming companies across enterprise and consumer technology sectors. As of April 2024, Crosslink closed its tenth flagship venture capital fund, Crosslink Ventures X, with $350 million in capital commitments, maintaining its focus on backing early-stage entrepreneurs from pre-seed through Series A stages​. A key component of Crosslink's strategy is the Alpha Network, an invite-only community of over 2,000 founders, CEOs, investors, and operators, established by General Partner Eric Chin in 2005. This network facilitates more than 40 annual events, including thematic discussions, networking parties, investor summits, and conferences, providing a rich ecosystem of support for founders. In conjunction with the recent fundraise, Crosslink has added Anduena Zhubi as the Director of Business Development, aimed at enhancing post-investment support for portfolio companies. Zhubi brings extensive industry experience from her previous roles at Microsoft and its venture arm, M12.

Crossroad Venture Capital Fund (Crossroad FCP) is a Luxembourg-based open-ended venture capital fund whose units are listed on the Luxembourg Stock Exchange, making it one of the few publicly traded early-stage venture vehicles in Europe. Founded in 2010 and backed by the Generali Insurance Group as its primary LP, the fund focuses exclusively on early-stage Israeli companies with unique intellectual property, exceptional management teams, and strong potential for market penetration and growth. Generali's permanent capital backing gives Crossroad a longer investment horizon than typical closed-end funds. The fund invests at pre-seed and seed stages, deploying $1 million to $10 million per company across medical devices, information and communications technology, renewable energy, biotechnology, and pharmaceuticals. With 15 investments spanning healthtech, AI, biotech, energy, and pharma, Crossroad covers Israel's strongest technology sectors. The fund leverages Generali's multinational network and strategic relationships to add value beyond capital — particularly in commercialization support for Israeli companies seeking to scale into European markets. Crossroad's structure as a listed, open-ended fund backed by one of Europe's largest insurance groups differentiates it meaningfully in the Israeli deep tech ecosystem. This combination of stock exchange liquidity, permanent capital, and a marquee corporate LP provides portfolio companies with a credible long-term institutional partner at the earliest stages of company development.

Crowberry Capital, a venture capital firm based in Reykjavik, Iceland, and Copenhagen, Denmark, focuses on seed and early-stage investments in the Nordic region. Founded by Helga Valfells, Hekla Arnardottir, and Jenny Ruth Hrafnsdottir, the firm aims to support innovative and high-potential startups across various sectors, including technology, digital health, and gaming. The firm has raised Iceland’s largest VC fund, a $90 million vehicle, which supports their mission to back diverse and bold entrepreneurs. Crowberry Capital’s portfolio includes notable companies such as Mainframe Industries, a gaming studio developing cloud-native social sandbox MMO Pax Dei; Lucinity, an AI-powered anti-money laundering platform; and Garden.io, which automates cloud development processes. Other investments include companies like Dreamdata, which focuses on B2B revenue attribution, and Kind, a provider of digital communication tools for healthcare providers​. Crowberry Capital prides itself on a strong follow-through philosophy, offering not only capital but also strategic support to help startups scale. Their approach has attracted significant interest from US VC funds at the Series A stage, highlighting the collaborative and robust nature of the Nordic startup ecosystem​.

CRV (formerly Charles River Ventures) is a well-established venture capital firm, founded in 1970, that focuses on early-stage investments in both enterprise and consumer technology startups. With over five decades of experience, CRV has supported the growth of more than 600 companies, including major successes like DoorDash, Airtable, Postman, and HubSpot. The firm is known for its hands-on approach and long-term commitment to helping founders build transformative companies. CRV typically leads investments and prides itself on moving quickly, often providing a term sheet within 24 hours. The firm aims to be a founder's first check, backing ambitious projects even in their earliest stages. They invest across various sectors, from enterprise software to consumer products, with notable focus areas like APIs (Postman), cloud networking (Aviatrix), and no-code solutions (Airtable). The firm’s investment ethos is built on forming deep, lasting partnerships with entrepreneurs, helping them navigate challenges and scale their businesses. CRV has offices in San Francisco and Palo Alto, California, with a team of partners experienced in working with startups through both good times and bad.

Crystal Horse Investments (CHI) is a Singapore-based venture capital firm with a focus on early-stage, angel, and seed investments. Established to support innovative startups across Southeast Asia, CHI has built a strong reputation for identifying high-potential companies, particularly in the technology, mobile, gaming, and web-based sectors. The firm actively participates in early funding rounds, including pre-seed, seed, and occasionally Series A, offering startups the critical capital and guidance they need to scale rapidly in competitive markets. Beyond just financial investment, CHI operates as an incubator, providing hands-on mentorship and strategic support to its portfolio companies. Startups benefit from Crystal Horse’s extensive network, industry insights, and operational expertise, allowing them to accelerate growth and navigate common early-stage challenges. The firm also collaborates with government initiatives such as Singapore’s iJam Reload program, which aims to nurture the next generation of tech innovators by providing incubation, mentorship, and early-stage funding opportunities. CHI has backed a diverse range of companies, from mobile app developers to cutting-edge web technology firms. With a strong belief in fostering innovation, CHI is committed to supporting entrepreneurs who are building the future of Southeast Asia’s digital economy. Their flexible investment approach, coupled with deep market knowledge, makes Crystal Horse a valuable partner for startups aiming to disrupt industries and scale regionally.

Cultivation Capital is a venture capital firm focused on early-stage investing, primarily at the Seed and Series A phases, with initial investments ranging from $100,000 to $3.5 million. Founded in 2012, the firm manages a family of funds targeting sectors such as life sciences and health tech, software and IT, agriculture and food tech, and geospatial technology. The firm has a mission to advance entrepreneurs with capital, counsel, and support while exceeding investors' expectations and creating opportunities for its team through career advancement and community impact. The firm operates several specialized funds, including partnerships with entities like the Yield Lab for Food and AgTech investments, and has backed over 120 startups. Notable investments include companies in diverse sectors such as therapeutics, diagnostics, precision agriculture, and location intelligence. Cultivation Capital is committed to building an inclusive portfolio, having invested in startups across more than 25 states and countries. The leadership team includes experienced venture capitalists and industry experts like co-founders Cliff Holekamp and Brian Matthews, as well as general partners and advisors with extensive backgrounds in their respective fields. The firm emphasizes active involvement with its portfolio companies, often taking board positions to provide strategic guidance and leverage their network of partners and investors.

Cultivian Sandbox Ventures is a venture capital firm dedicated to investing in innovative startups within the food and agriculture sectors. Founded in 2008 and headquartered in Chicago, the firm focuses on technologies that enhance crop production, animal health, food safety, and sustainability​. The firm has a robust portfolio featuring companies such as Vestaron, which is leading advancements in peptide-based crop protection, Supergut, offering functional food products for gut health, and Sound Agriculture, which develops products to help plants utilize soil nutrients more effectively​​. They also back companies like Geltor, which produces animal-free protein ingredients, and Full Harvest, a B2B marketplace for surplus produce​ (Cultivian Sandbox Ventures)​. Cultivian Sandbox Ventures recently closed its third fund at $135 million, with prominent investors including Archer Daniels Midland, Corteva Agriscience, and Ecolab. This fund focuses on Series A and B deals, with a global investment scope, looking particularly at synthetic biology, AI, and advanced materials​​. The team is led by experienced professionals like Andy Ziolkowski, who has over 30 years in venture capital and merchant banking, and Dan Phillips, who emphasizes the firm's commitment to platform technologies with multiple market applications​.

Cure Kids Ventures (CKV) is a seed and early-stage venture capital fund based in Auckland, New Zealand, established in 2008 as part of Cure Kids, a leading child health research charity. CKV invests in the commercialization of innovations that have the potential to improve child health globally. The fund focuses on healthcare-related sectors, including medical devices, biotechnology, diagnostics, medications, and health information systems. Its mission aligns closely with Cure Kids’ vision of a healthier future for children, supporting solutions that can make a significant impact on pediatric care​. CKV typically invests in pre-seed, seed, and Series A rounds, with initial investments ranging from under $500,000 to $3 million. The fund is highly selective, emphasizing strong commercialization potential. CKV has built an impressive portfolio, backing companies like the a2 Milk Company, Pictor, and The Clinician, which are making waves in health tech and biotech industries. Their investments are strategically aimed at driving innovations that address critical health challenges faced by children. The team at CKV brings global experience in biotechnology and healthcare, providing not only financial backing but also valuable insights into early-stage development and commercialization. CKV has played a crucial role in fostering the growth of New Zealand’s healthcare innovation ecosystem, and its impact extends beyond capital, as it works closely with startups to help them achieve market success.

Cure Ventures, based in Boston, Massachusetts, is a life sciences venture capital firm founded in 2021. The firm focuses on early-stage investments in biotechnology, particularly in new therapeutics. They aim to drive groundbreaking curative technologies from concept to clinical success. Cure Ventures closed their inaugural fund at $350 million, indicating substantial resources dedicated to their mission. The investment strategy at Cure Ventures emphasizes genetic validation to guide drug development, thus increasing the probability of success while reducing the cost of failure. They use a seed funding model to de-risk scientific ventures, with plans to co-lead Series A and B rounds for promising companies. Their hands-on approach involves embedding Cure operators within portfolio companies to assist with day-to-day decision making​. The team at Cure Ventures includes co-founders Richard Lim, David Fallace, and Lou Tartaglia, who bring extensive experience from successful biotech firms like Juno Therapeutics and Agios Therapeutics. Their backgrounds provide a strong foundation for supporting startups through scientific and operational challenges. Notable investments by Cure Ventures include Clasp Therapeutics, Kenai Therapeutics, and Tasca Therapeutics, reflecting their focus on innovative biotechnological solutions. Startups looking to approach Cure Ventures should highlight their potential for breakthrough therapies and be prepared for an intensive, collaborative partnership aimed at achieving significant medical advancements.

CyberAgent Capital (CAC) is a prominent venture capital firm specializing in early-stage investments, particularly in internet and technology-based startups. Founded in 2006 as part of the larger CyberAgent Group, the firm focuses on companies in the seed and early-growth stages. With a strong global network, CAC operates across key markets in Asia, including Japan, China, Taiwan, Indonesia, Vietnam, and Thailand, offering startups a bridge to regional and global expansion. The firm’s investment philosophy centers on incubating and accelerating internet-based businesses. CAC provides deep strategic and operational support, particularly in user acquisition, UI/UX design, and marketing strategies. This hands-on approach allows startups to leverage CAC’s extensive industry knowledge and its connection to the CyberAgent Group, fostering quicker growth in fast-moving markets​. CyberAgent Capital typically invests in startups aiming for global reach and scalability, helping them expand across borders. The firm manages several funds and offers flexible investment sizes depending on the growth stage, supporting companies from the initial idea phase to market expansion​. Some of CAC’s notable portfolio companies include Tokopedia, Coda Payments, and Viddsee, which highlight the firm’s successful track record in backing high-potential tech-driven ventures​.

DAAL Ventures is a venture capital firm headquartered in Saudi Arabia, focusing on early-stage investments in the technology sector, particularly in emerging markets. Founded with the mission to bridge international innovation and the Middle East, DAAL plays a pivotal role in helping startups expand into the GCC region, especially Saudi Arabia. The firm is known for providing not only capital but also strategic guidance and mentorship to its portfolio companies. DAAL leverages its extensive regional network and expertise to support startups in various sectors, including fintech, SaaS, artificial intelligence (AI), Internet of Things (IoT), and big data. DAAL Ventures stands out for its collaborative approach, positioning itself as a partner to the companies it backs. This involves helping entrepreneurs scale their operations globally and connecting them with world-class investors and local partners in the Middle East. The firm has invested in a diverse range of startups, including Pulppo, a Mexican proptech platform, and Paym.es, a fintech company, highlighting its commitment to identifying high-potential tech ventures across different regions​. The firm’s vision is to be a leader in tech-focused venture capital in Saudi Arabia and the broader GCC region. DAAL is committed to fostering growth by offering operational support, business development resources, and access to its network of strategic partners. This positions DAAL Ventures as a key player for startups looking to break into the Middle Eastern market​.

Danone Ventures, the corporate venture arm of Danone, is at the forefront of investing in groundbreaking startups within the food and beverage industry. Notable investments include Farmer's Fridge, Harmless Harvest, and Michel et Augustin, demonstrating their commitment to supporting innovative brands that push the boundaries of health and sustainability. With a strategic focus on early-stage companies, Danone Ventures targets sectors such as plant-based products, sustainable food systems, and personalized nutrition. Their geographic reach spans across North America, Europe, and increasingly into emerging markets, showcasing a global outlook with a local touch. Danone Ventures employs a proactive investment strategy, often taking significant stakes and leading funding rounds. They typically invest between $1M and $10M, providing not just capital but also leveraging Danone's extensive resources to help startups scale. The firm has shown consistent activity, with recent investments in companies like Nature’s Fynd and Ready, Set, Food!, highlighting their commitment to innovation and sustainability. The team at Danone Ventures includes experts like Laurent Marcel and Emmanuel Faber, who bring deep industry knowledge and a passion for transforming the food landscape. Startups looking to partner with Danone Ventures should emphasize their innovative approach and alignment with Danone's mission of bringing health through food to as many people as possible. Being approachable and showcasing strong market potential are key to gaining their interest. Danone Ventures is dedicated to fostering a healthier world through strategic and impactful investments.

Daphni Ventures, based in Paris, was founded in 2016 and focuses on early-stage investments with a European DNA and strong international ambition. The firm aims to support companies that contribute to making the world a better place through innovative and disruptive models, emphasizing social and environmental sustainability. Daphni's investment thesis revolves around empowering founders to create a sustainable future by leveraging deep tech and innovation. The firm has made over 80 investments and has seen multiple successful exits, including Shine.fr, Masteos, and Foxintelligence. Their portfolio includes a wide range of companies such as ZOE, a personalized nutrition platform; Double, a remote executive assistant service; and Masteos, a full-stack real estate agency. They also back companies in sectors like edtech, fintech, and health tech, supporting ventures that focus on the circular economy, upcycling, social inclusion, and the future of work. Daphni operates three main investment vehicles: Purple, Yellow, and Dastore, each focusing on different areas of innovation and sustainability. Their approach involves not only providing capital but also offering operational support and access to a community of experts to facilitate collaboration and knowledge-sharing among their portfolio companies.

Darling Ventures is an early-stage venture capital firm based in San Francisco, focusing on providing seed funding to startups with disruptive potential. The firm invests primarily in pre-seed and seed rounds, with check sizes ranging from $50,000 to $250,000. Darling Ventures has built a reputation for backing innovative technology companies, especially in sectors such as digital health, AI, SaaS, fintech, and cloud infrastructure. Their hands-on approach to investing involves closely supporting portfolio companies with growth strategies, market expansion, and preparing for subsequent funding rounds. The firm's portfolio includes startups like Everlywell, Hummingbird, and Berbix, showcasing their commitment to scaling tech-driven solutions in industries with significant growth potential. With a global focus, Darling Ventures leverages its network and expertise to guide founders toward successful outcomes, ensuring they are well-positioned for the next stages of their journey. Founded by Daniel Darling, the firm prides itself on identifying early-stage opportunities in high-growth sectors and helping companies reach product-market fit quickly. Darling Ventures often works as a lead investor but also collaborates with other VCs to maximize the chances of success for the companies in its portfolio. Their strong involvement in their investments sets them apart, offering more than just capital to founders—they bring strategic advice, mentorship, and connections to the table.

Day One Capital, founded in 2011, is a venture capital firm based in Budapest, Hungary, focusing on early-stage technology startups primarily in the Central and Eastern European (CEE) region. They are known for their investments in B2B software companies, leveraging the region's strong talent pool to support technology-driven founders. Day One Capital has built a diverse portfolio across various industries, including AI, fintech, and logistics. Notable investments include Turbine AI, which uses simulated cell technology to enhance drug discovery; Webshippy, a logistics and fulfillment service provider; and Volteum, a company aiding electric vehicle fleet management. They have also backed companies like Colossyan, which specializes in generative AI for video editing, and Commsignia, a leader in automotive IoT​. Their typical investment range is from €300k to €1.5 million for seed and Series A rounds. They have been instrumental in helping companies scale globally, providing not only capital but also strategic support and mentorship from their experienced team, which includes former government officials and seasoned investors​​. Day One Capital continues to foster growth and innovation within the CEE region, contributing significantly to the local startup ecosystem and helping companies achieve successful exits, such as AImotive's acquisition by Stellantis and NOW Technologies' acquisition by Sunrise Medical​​.

Day One Ventures, founded by Masha Bucher in 2018, is a dynamic early-stage venture capital firm based in San Francisco. Known for their unique approach, they combine investment with hands-on PR and communication support, setting them apart in the VC landscape. The fund focuses on industries such as fintech, climate and energy, AI, deep tech, consumer products, and enterprise solutions, with a geographic emphasis on North America and Europe. Their portfolio boasts notable investments in companies like DuckDuckGo, Remote, WorldCoin, and Superplastic. Day One Ventures typically invests between $100K and $1M, often leading seed and Series A rounds. They have a strong track record, with 22 exits and several unicorns under their belt, aggregating over $115 billion in value. Masha Bucher, a Forbes 30 Under 30 honoree and former PR executive, leverages her extensive communications background to provide unparalleled support to portfolio companies, from media strategy to investor introductions. The team, including key members like Drake Rehfeld and Tara Harandi-Zadeh, is deeply involved in every step of the startups' journeys, fostering a close-knit community.

DCM Ventures, founded in 1996 and based in Menlo Park, California, is a prominent venture capital firm known for its extensive portfolio and successful investments. With over $4 billion under management, DCM focuses on early-stage technology companies across the U.S., China, and Japan. Notable investments by DCM Ventures include companies like SoFi, Careem, Fortinet, and Matterport. These companies highlight DCM’s diverse investment strategy, spanning fintech, cybersecurity, consumer internet, and enterprise software. The firm has also backed companies like Bill.com and Musical.ly (now TikTok), which have seen significant growth and success​​. DCM Ventures operates with a global perspective, investing in the three largest technology markets: the U.S., China, and Japan. This strategic approach has enabled DCM to deliver strong returns to its limited partners, with a focus on early-stage SaaS, fintech startups, and consumer internet companies. The firm has seen numerous successful exits, with 254 companies in its portfolio going public or being acquired​​. The leadership team at DCM includes co-founders David Chao and Xinhe Lin, who guide the firm’s global investment strategy and operational support to its portfolio companies. For startups looking to connect with DCM Ventures, demonstrating innovative solutions in high-growth sectors such as fintech, AI, and cybersecurity can align well with the firm’s investment focus​.

DCVC (Data Collective Venture Capital) is a deep tech venture capital firm based in Palo Alto, California, founded in 2010 by Matthew Ocko and Michael Driscoll. The firm focuses on investing in groundbreaking technologies that address significant global challenges across various sectors, including artificial intelligence, space, climate, engineering, and more. DCVC manages multiple funds, including DCVC V, which is a $725 million fund aimed at disrupting substantial sectors of the global economy. The firm emphasizes backing startups that employ computational and engineering approaches to solve high-stakes problems. Notable portfolio companies include Pivot Bio, Planet, Zymergen, Atomwise, Rocket Lab, and Recursion Pharmaceuticals, all of which are leaders in their respective industries. DCVC also has a specialized branch, DCVC Bio, co-founded with Dr. John Hamer and Dr. Kiersten Stead, focusing on AI-enabled life sciences platforms. This branch aims to bring new medicines to market and commercialize biological breakthroughs, with companies like AbCellera, Chroma Medicine, and Totus Medicines leading the charge​. The firm’s investment strategy is driven by a belief that venture capital can address urgent global problems profitably and equitably, turning challenges into opportunities while delivering strong returns. DCVC continues to expand its team with experts across various fields to support its growing portfolio and mission​.

De Novo Ventures was a Menlo Park, California-based venture capital firm founded in 2000 by Richard Ferrari and David Mauney, specializing exclusively in medical devices and biotechnology. The firm managed approximately $650 million across three funds, with its largest — De Novo Ventures III LP — reaching $300 million. Over its lifetime, De Novo backed more than 40 companies and led rounds throughout early and growth stages. The portfolio produced a strong exit track record: Pulmonx went public on NASDAQ at a $645 million market capitalization, EBR Systems listed on the ASX in 2021, and AxoGen completed a public offering, alongside 25 acquisitions across the portfolio. Additional companies included EndoGastric Solutions, TRIA Beauty, Benvenue Medical, and Milo. Average checks ranged from $3 million to $50 million, reflecting the capital-intensive nature of medical device development. Richard Ferrari, the managing director, brought over 35 years of medical device entrepreneurship to the partnership, having previously led CardioThoracic Systems to IPO and Cardiovascular Imaging Systems to acquisition by Boston Scientific. De Novo Ventures combined that operational depth with patient capital structured for the long regulatory cycles inherent to life sciences. The firm is now permanently closed; its most recent portfolio activity was the acquisition of TRIA Beauty by CurrentBody in October 2024.

Decent Capital, founded in 2007 by Jason Zeng, co-founder of Tencent, is a prominent venture capital firm with a global presence. The firm focuses on early-stage investments across sectors such as SaaS, consumer internet, frontier tech, and sustainable technology, with investments ranging from pre-seed to Series A stages. Decent Capital’s diverse portfolio includes notable companies like Lime, Cider, and Huizuche. Lime is well-known for its smart scooters and bikes aimed at addressing last-mile transportation issues, while Cider is a direct-to-consumer e-commerce platform for fashion. Huizuche, another significant investment, focuses on car rental services in China. The firm has seen successful exits, such as the acquisition of Oculii and Huizuche, and the IPO of FangDD on NASDAQ in 2019. The firm’s investment strategy emphasizes supporting companies through their growth stages with continued capital and strategic guidance. Decent Capital operates from multiple locations, including offices in Shenzhen, Hong Kong, Singapore, and the United States, ensuring a broad reach and impact across various markets.

Deep Science Ventures (DSV) is a London-based venture studio founded in 2016 that specializes in building science-driven startups across four key sectors: agriculture, computation, climate, and pharmaceuticals. DSV's approach is unique in that it combines scientific knowledge with entrepreneurial expertise to create high-impact ventures from scratch. They partner closely with founder-scientists to tackle some of the world's most pressing challenges, such as reversing global warming, developing curative therapeutics, and advancing computational technologies. DSV's portfolio includes a diverse range of companies, such as Mission Zero Technologies, which focuses on energy-efficient direct air capture of CO2, and Neobe Therapeutics, which is engineering bacteria to improve the efficacy of cancer immunotherapy. These ventures reflect DSV's commitment to creating transformative solutions that are both scientifically rigorous and commercially viable. The firm's model emphasizes de-risking ventures through deep technical and market analysis before significant capital is committed. This methodical approach ensures that the startups they create have a strong foundation for long-term success.

Deepbridge Capital, established in 2010 and headquartered in Chester, UK, focuses on providing growth capital to companies in the technology, life sciences, and renewable energy sectors. Their investment approach emphasizes supporting innovative and high-growth potential companies through various tax-efficient investment opportunities. Deepbridge Capital's portfolio includes a diverse array of companies. Notable investments are in firms like AlgaeCytes, which specializes in producing high-quality EPA oils from algae, and VoxSmart, which provides compliance management solutions for banks. They have also invested in promising startups like Thalia Design Automation, an AI-driven EDA platform, and Ibis Vision, a cloud-based vision testing software for the optical industry. The firm has made 168 investments and has seen 101 exits, showcasing their experience and success in nurturing companies to achieve significant milestones. Deepbridge Capital also supports companies through initiatives such as the Deepbridge Technology Growth EIS Fund and the Deepbridge Innovation SEIS Fund, offering financial backing and strategic guidance to early-stage businesses. The Deepbridge team, led by Managing Partner Ian Warwick, is known for their commitment to fostering innovation and growth across their investment sectors. For more information about their investments and strategic approach, you can visit their official website.

The DeepTech & Climate Fonds (DTCF) is a German venture capital fund aimed at supporting growth-stage startups working on transformative technologies in sectors such as deep tech and climate tech. Established in 2023, the fund has a capital pool of €1 billion, sourced from Germany’s Future Fund and the European Recovery Program. It focuses on companies developing solutions in fields like Industry 4.0, quantum computing, AI, and clean energy technologies. DTCF primarily invests in companies that require long development cycles and substantial capital, providing them with the resources to scale their innovations across Europe. The fund works as an anchor investor, partnering with institutional investors, family offices, and private capital to ensure that these companies can achieve commercial success and contribute to a climate-neutral economy. Led by Dr. Elisabeth Schrey and Tobias Faupel, DTCF has already made notable investments in companies like Membion, which focuses on wastewater recycling, and Cylib, a battery recycling startup. The fund's mission is to drive systemic change by investing in technologies that will reshape industries and contribute to sustainability across the European tech landscape​.

DeepWork Capital, established in 2015 and based in Orlando, Florida, is an early-stage venture capital firm. The firm primarily targets technology and life sciences startups, particularly those in U.S. regions traditionally underserved by venture capital. DeepWork Capital's investment strategy focuses on seed and Series A stage companies, often being the first institutional capital after friends, family, and angel investors. Their portfolio includes a diverse range of companies such as AbFero Pharmaceuticals, acquired by Pharmacosmos, and AireHealth, addressing respiratory challenges. Other notable investments include Astrocyte Pharmaceuticals, developing therapeutics for brain injury, and Genascence, working on gene therapy for musculoskeletal diseases. The firm also supports innovative startups like Nanophotonica, which is pioneering EL-QLED technology, and Homee, which digitizes insurance claims processes. The DeepWork Capital team, including Managing Partners Mitchel Laskey, Ben Patz, and Kathy Chiu, brings a wealth of experience from various industries. The firm emphasizes a hands-on, active engagement approach, supporting entrepreneurs before, during, and after investment. DeepWork Capital's mission is to foster innovation in regions like Florida by providing necessary capital and strategic support to tech-forward founders committed to solving significant societal challenges.

Deerfield Management, a prominent investment firm based in New York City, is dedicated to advancing healthcare through strategic investments, information, and philanthropy. With over $14.6 billion in assets under management, Deerfield maintains a diverse portfolio of more than 200 private and public investments across biotechnology, pharmaceuticals, medical devices, healthcare services, and digital health industries​ . Notable portfolio companies include Graphcore, JFrog, and Netskope. The firm has a strong track record of supporting startups from early stages to mature companies, offering flexible funding models, including equity, debt, and joint ventures. Deerfield’s investment approach is characterized by deep operational support and a robust network of strategic partners and academic collaborations​ ​. Deerfield’s team comprises over 150 experienced professionals with expertise in various sectors of healthcare and finance, ensuring comprehensive support for their portfolio companies. The firm’s initiatives, such as the Deerfield Discovery and Development (3DC) and the Cure Campus, further highlight their commitment to fostering innovation and addressing complex health issues​​. The Deerfield Foundation, part of the firm’s philanthropic efforts, focuses on improving healthcare delivery, particularly for underserved populations, and has invested over $68 million in various health initiatives.

Define Ventures is a premier early-stage venture capital firm, singularly focused on investing in digital health companies. With a keen eye for transformative potential, Define Ventures partners with innovative entrepreneurs to reshape the healthcare landscape. Their portfolio features notable investments such as Blackbird Health, which is revolutionizing pediatric mental health, and Lightship, a pioneer in decentralized clinical trials. Define Ventures operates primarily within the digital health sector, focusing on business models that integrate technology and healthcare to create scalable solutions. Geographically, they concentrate their efforts within the United States, fostering close relationships with startups that promise substantial impact in the national healthcare system. The firm’s strategy centers on leading early-stage funding rounds, including incubation, seed, Series A, and Series B stages. Define Ventures is renowned for their hands-on approach, providing not just capital but also strategic guidance and industry expertise to help their portfolio companies thrive. The team is led by industry veterans like Lynne Chou O'Keefe, the founder and managing partner, whose vision drives the firm's success. Other key members include A.G. Breitenstein and Frank Williams, both of whom bring extensive experience in healthcare and digital innovation. Define Ventures has recently closed $460 million across Fund III and an Opportunities Fund, cementing its position as a significant player in digital health investment.

Defy Ventures, a New York-based venture capital firm founded in 2010 by Catherine Hoke, focuses on early-stage investments and supporting entrepreneurs, particularly those with unconventional backgrounds such as former convicts. The firm is dedicated to fostering entrepreneurship, employment, and character training for its community. Defy's portfolio includes notable companies such as Nautilus Biotechnology, Empower, and Shujinko. They have made significant investments in various sectors, including high tech, business services, and food and agriculture tech. Recent investments include Monitaur, Writ, and Delivery Collective. The firm values authenticity and the tenacity needed to transform bold ideas into lasting companies. Defy Ventures aims to be the partner of choice for today's daring startup founders, helping them become tomorrow's visionary leaders. They emphasize working behind the scenes to amplify the success of their portfolio companies.

Delin Ventures is a UK-based, mission-driven venture capital firm that focuses on early-stage investments, specializing in two key areas: Life Sciences and the Future of Work & Learning. Established in 2015, the firm backs founders working on breakthrough technologies that can transform healthcare through cell therapies and the future of human work and learning. Delin invests in pre-seed and seed rounds, with typical ticket sizes ranging from €100,000 to €1.5 million, primarily in European startups. In the Life Sciences domain, Delin is committed to advancing cell therapy solutions that can either cure life-threatening diseases or transform them into manageable, chronic conditions. They also invest in the infrastructure necessary for the development and commercialization of these therapies. Notable investments include startups working on innovative therapeutics, medical services, and manufacturing technologies. In the Future of Work & Learning sector, Delin Ventures aims to unlock human potential by investing in technologies that shape the workforce of tomorrow. This includes HR tech, productivity tools, workforce development, and upskilling platforms. They provide hands-on support to founders, leveraging their deep operational expertise and extensive network. The team, led by founder Igor Linshits, includes experts from various industries, ensuring a strong focus on long-term impact. Delin's strategy is centered around making fewer, high-quality investments to ensure that they can offer exceptional support to their portfolio companies, which includes businesses like Fluidic Analytics, Vidsy, and Ori Biotech. The firm is highly selective, providing patient capital and working closely with founders to scale impactful solutions.

Demeter, a major European player in venture capital, private equity, and infrastructure, focuses on investments that drive the energy and ecological transition. Founded in 2005, Demeter manages €1.3 billion across its funds and has completed over 230 investments. The firm targets innovative startups, SMEs, and infrastructure projects, offering investments ranging from €1 million to €30 million. Notable investments include McPhy Energy, which specializes in hydrogen production, storage, and distribution technologies, and Ynsect, which produces environmentally friendly insect-based products. Demeter also supports companies like Sunna Design, which develops solar LED lighting solutions, and Sweetch Energy, a renewable energy firm focusing on osmotic energy. One of Demeter's significant initiatives is the recent launch of a €500 million fund in collaboration with EIT InnoEnergy. This fund aims to develop a resilient and diverse battery raw material supply chain for Europe, addressing the continent's growing demand for batteries and supporting the European Battery Alliance's goals. Demeter's investment strategy is driven by a commitment to sustainability, evident in their support for green projects like H2 Green Steel, the world's first integrated large-scale green steel plant. The firm's dedication to environmental responsibility is further reflected in their involvement in initiatives like the Climate Dividends program, which promotes sustainability across their portfolio companies.

Derayah Ventures is a Saudi-based venture capital firm that invests in early to growth-stage startups across the MENA region. Launched in 2019, the firm manages a $30 million fund focused on technology-driven businesses, particularly in sectors such as SaaS, fintech, eCommerce, artificial intelligence, Internet of Things (IoT), and marketplace platforms. Derayah primarily backs companies that are either disrupting traditional industries or organizing them through innovative solutions. The firm’s investment philosophy centers on supporting scalable startups with high growth potential and strong teams. Derayah Venture Capital provides not just financial backing but also strategic guidance to help companies expand within the MENA region, especially into Saudi Arabia. The fund focuses on post-seed, pre-Series A, and Series A stages, enabling startups to access critical capital during their early development phases. Led by a team of experienced investors, including Chairman Faris Ibrahim AlRashed, Derayah aims to build tomorrow's market leaders through a combination of capital, industry expertise, and strong local networks.

Detroit Venture Partners (DVP), founded in 2010 by Dan Gilbert, is a venture capital firm committed to backing early-stage tech startups that aim to drive innovation and economic growth. Based in Detroit, DVP is part of the broader Rock Family of Companies, which includes Rocket Companies, Bedrock Detroit, and the Cleveland Cavaliers. This extensive network enables DVP to offer its portfolio companies not only financial backing but also strategic partnerships and resources to help them scale effectively. DVP focuses on investing in startups that embody creativity, grit, and passion. They have a strong emphasis on companies in the technology sector, including fintech, SaaS, and logistics. Some of their notable portfolio companies include StockX, Livegistics, 100 Thieves, and CoverTree. By fostering innovation, DVP contributes to Detroit’s entrepreneurial ecosystem, helping to rejuvenate the city’s long history of industrial innovation. In addition to their investment activities, DVP runs a Summer Fellowship program that offers MBA and undergraduate students hands-on experience in venture capital and early-stage startups.

Development Capital, established in 2013 and headquartered in Dublin, is an Irish growth capital fund manager focused on scaling mid-sized, profitable Irish SMEs with strong export potential. The firm typically invests between €2 million and €12 million in ambitious companies, using flexible financing structures such as equity, quasi-equity, or debt, and typically holds minority stakes with a five-year investment horizon. Development Capital is committed to supporting companies with growth strategies, ranging from international expansions to strategic acquisitions and production capacity increases. The fund’s €75 million Fund II, supported by the European Investment Fund and the Ireland Strategic Investment Fund, targets Irish SMEs poised for international growth. Notable portfolio companies include Version 1, a leading IT services provider, and Spotlight Oral Care, a premium oral care brand. Through their investments, Development Capital has helped companies like Perigord expand globally and develop new products. Perigord, a leader in life sciences packaging, was acquired by Tech Mahindra, allowing Development Capital to successfully exit its investment. The firm prides itself on offering more than just capital. It partners closely with management teams to maximize growth potential, bringing industry experience and market insights to every engagement. With a focus on responsible investing, Development Capital integrates ESG factors throughout its investment process, ensuring sustainable and impactful growth for its portfolio companies.

Dexcel Pharma is the largest private pharmaceutical company in Israel, renowned for its extensive portfolio of branded and generic drugs. Founded in 1968, the company has grown into a global player, with state-of-the-art R&D and manufacturing facilities that support the development and commercialization of innovative and cost-effective pharmaceutical products. Dexcel's product portfolio spans across various therapeutic areas, including small molecules, biologics, and RNA-based therapies. The company is committed to advancing science through substantial investments in R&D, particularly in cutting-edge fields like siRNA therapeutics and oligonucleotides. Their innovation initiatives include the creation of specialized entities like Dexoligo Therapeutics, which focuses on RNA-based medicines, and Clexio Biosciences, which develops treatments for neurological and psychiatric conditions. With over 1,200 employees and a strong presence in key markets like the United States, Germany, and the UK, Dexcel manufactures over 5 billion oral-solid dosages annually. The company maintains a reputation for quality, with its facilities meeting global standards and holding approvals from regulatory bodies like the FDA and EMA.

DHVC, founded in 2013 by Shoucheng Zhang, is a venture capital firm based in Palo Alto, California. The firm focuses on early-stage investments across several sectors, including enterprise, consumer, fintech, and healthcare. Over the years, DHVC has built a substantial portfolio, investing in over 267 companies with 75 successful exits​. DHVC has also seen significant exits with companies like Wish Shopping, Qeexo, and Namocell, indicating their strong presence in the tech investment space. The firm’s investment strategy involves participating in a mix of seed, early-stage, and later-stage funding rounds, often co-investing with other prominent venture capital firms​. The DHVC team, led by key members such as Kevin Ding and Judy Yan, brings a wealth of experience and a global perspective to their investment approach. The firm’s operations are split between the United States and China, allowing them to leverage opportunities across major innovation hubs​.

DIC Corporation operates a Corporate Venture Capital (CVC) unit that focuses on strategic investments aligned with their core mission of sustainable innovation. Founded as a global leader in fine chemicals, DIC leverages its venture capital arm to support startups that bring new, disruptive technologies in areas like biomanufacturing, advanced materials, and industrial IT. Their investment strategy aims to complement their existing businesses in sectors such as color science, healthcare, and packaging. Recent notable investments include funding Debut Biotechnology, a California-based company specializing in sustainable biomanufacturing. This partnership allows DIC to accelerate the development of bio-based materials, particularly natural pigments for cosmetics and nutrition, aligning with their long-term vision of sustainability under the DIC Vision 2030 plan. DIC's CVC activities also extend to partnerships with other venture funds, such as their collaboration with Emerald Technology Ventures, which focuses on industrial innovation in clean technology. DIC’s strategic approach to venture investing helps them explore new markets while enhancing their capabilities in sustainable products, driving innovation across their global network of over 190 companies.

Digital Currency Group (DCG), founded in 2015 by Barry Silbert, is a prominent venture capital firm dedicated to accelerating the development of a better financial system through investments in blockchain and digital currency companies. With over 200 equity investments in more than 30 countries, DCG has established itself as the most active investor in the digital asset industry. DCG owns and operates several leading businesses within the crypto ecosystem. These include CoinDesk, a top media, research, and events platform; Genesis, a major institutional lending and brokerage firm; Grayscale Investments, the largest digital currency asset management firm; Foundry, which focuses on digital asset mining and staking; and Luno, a global digital asset exchange and wallet provider​. Their investment strategy encompasses a broad array of sectors such as payments, privacy, stablecoins, trading tools, Web3 infrastructure, DeFi, and NFTs, among others. DCG supports companies at various stages of development, from seed and venture to growth and public markets, ensuring comprehensive support through all phases of their growth​.